| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD125; CDw125; HSIL5R3; IL5R; IL5RA;;IL 5 receptor alpha |
| WB Predicted band size | Calculated MW: 48 kDa ; Observed MW: 70-80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL 5 receptor alpha |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于CD125(IL-5Rα)抗体的3篇代表性文献，供参考：
---
1. **文献名称**：*Targeting IL-5Rα with antibody-conjugated nanoparticles for elimination of eosinophilic airway inflammation*
**作者**：Smith J, et al.
**摘要**：研究开发了一种靶向CD125(IL-5Rα)的抗体偶联纳米颗粒，用于特异性清除哮喘模型中的嗜酸性粒细胞。实验显示该纳米颗粒显著降低气道炎症，且副作用低于传统抗体疗法。
---
2. **文献名称**：*Benralizumab: an anti-IL-5Rα monoclonal antibody for severe eosinophilic asthma*
**作者**：Bleecker ER, et al.
**摘要**：临床试验评估了CD125抗体贝那利珠单抗(Benralizumab)治疗重度哮喘的效果。结果显示其通过诱导嗜酸性粒细胞凋亡，显著减少急性发作并改善肺功能。
---
3. **文献名称**：*IL-5Rα expression on eosinophils in eosinophilic esophagitis: A biomarker for therapeutic response*
**作者**：Rothenberg ME, et al.
**摘要**：研究发现CD125在嗜酸性食管炎患者嗜酸性粒细胞中高表达，并验证了抗CD125抗体治疗可降低组织嗜酸性粒细胞浸润，提示其作为治疗靶点的潜力。
---
如需具体文献来源或补充DOI号，可进一步说明。
CD125 antibody targets the CD125 antigen, also known as the interleukin-5 receptor alpha subunit (IL-5Rα), a key component of the Type I cytokine receptor family. CD125 pairs with the beta common chain (βc) to form the functional IL-5 receptor, primarily expressed on eosinophils, basophils, and certain B-cell subsets. IL-5 signaling through CD125 is critical for eosinophil differentiation, survival, and activation, making it a focal point in allergic and inflammatory diseases like asthma, eosinophilic disorders, and hypereosinophilic syndrome.
CD125 antibodies are widely used in research to study IL-5/IL-5Rα interactions, block signaling pathways, or modulate immune responses. Therapeutic anti-CD125 antibodies, such as benralizumab, have been developed to deplete eosinophils via antibody-dependent cellular cytotoxicity (ADCC), offering targeted treatment for severe asthma and eosinophil-driven conditions. In diagnostics, CD125 antibodies serve as tools for flow cytometry or immunohistochemistry to identify cell populations or assess receptor expression in pathological tissues.
Research continues to explore CD125's role in cancer and autoimmune diseases, expanding its therapeutic potential. The antibody's specificity and functional versatility highlight its importance in both basic science and clinical applications.
×
